TY - JOUR
T1 - Lead inhibits secretion of osteonectin/SPARC without significantly altering collagen or Hsp47 production in osteoblast-like ROS 17 2.8 cells
AU - Sauk, John J.
AU - Smith, Timothy
AU - Silbergeld, Ellen K.
AU - Fowler, Bruce A.
AU - Somerman, Martha J.
N1 - Funding Information:
This research was supported by Agency for Toxic Substances and Disease Registry through Centers for Disease Control Project H75/ATH390067 awarded by the Maryland Department of the Environment in cooperation with University of Maryland at Baltimore, DE-08648 and AR-41 572 NIH. Thanks are extended to Ms. Jo-Ann Walker for preparation of the manuscript.
PY - 1992/10
Y1 - 1992/10
N2 - In an effort to better understand the consequences of lead (Pb2+) on skeletal growth, the effects of Pb2+ were investigated using ROS 17 2.8 bone-like cells in vitro. These studies revealed that Pb2+ (4.5 × 10-6 m - 4.5 × 10-7 m) has little or no effect on cell shape except when added immediately following seeding of the cells. However, proliferation of ROS cells was inhibited, in the absence of serum, at concentrations of 4.5 × 10-6 m Pb2+. Protein production was generally increased, however, the major structural protein of bone, type I collagen, production was only slightly altered. Following treatment of ROS cells with Pb2+, intracellular levels of the calcium-binding protein osteonectin/SPARC were increased. Osteonectin/SPARC secretion into the media was delayed or inhibited. Coincident with retention of osteonectin/SPARC there was a decrease in the levels of osteonectin/SPARC mRNA as determined by Northern analysis. These studies suggest that processes associated with osteonectin/SPARC translation and secretion are sensitive to Pb2+.
AB - In an effort to better understand the consequences of lead (Pb2+) on skeletal growth, the effects of Pb2+ were investigated using ROS 17 2.8 bone-like cells in vitro. These studies revealed that Pb2+ (4.5 × 10-6 m - 4.5 × 10-7 m) has little or no effect on cell shape except when added immediately following seeding of the cells. However, proliferation of ROS cells was inhibited, in the absence of serum, at concentrations of 4.5 × 10-6 m Pb2+. Protein production was generally increased, however, the major structural protein of bone, type I collagen, production was only slightly altered. Following treatment of ROS cells with Pb2+, intracellular levels of the calcium-binding protein osteonectin/SPARC were increased. Osteonectin/SPARC secretion into the media was delayed or inhibited. Coincident with retention of osteonectin/SPARC there was a decrease in the levels of osteonectin/SPARC mRNA as determined by Northern analysis. These studies suggest that processes associated with osteonectin/SPARC translation and secretion are sensitive to Pb2+.
UR - http://www.scopus.com/inward/record.url?scp=0026705308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026705308&partnerID=8YFLogxK
U2 - 10.1016/0041-008X(92)90303-A
DO - 10.1016/0041-008X(92)90303-A
M3 - Article
C2 - 1412468
AN - SCOPUS:0026705308
SN - 0041-008X
VL - 116
SP - 240
EP - 247
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
IS - 2
ER -